Casele H L, Laifer S A
Department of Obstetrics and Gynecology, Evanston Hospital, Northwestern University Medical School, Illinois 60201, USA.
J Matern Fetal Med. 2000 Mar-Apr;9(2):122-5. doi: 10.1002/(SICI)1520-6661(200003/04)9:2<122::AID-MFM7>3.0.CO;2-Q.
To evaluate changes in bone density in women receiving enoxaparin sodium during pregnancy.
Bone density in the proximal femur was serially measured in 16 women receiving enoxaparin sodium (40 mg daily) during pregnancy. Baseline measurements were taken within 2 weeks of starting therapy and then at 6-8 weeks postpartum and 6 months postpartum.
Patients received enoxaparin sodium for a mean duration of 25 weeks (range, 19-32 weeks). There was no significant change in mean bone density measurement from baseline measurements to the conclusion of therapy at 6 weeks postpartum and no patient experienced a decrease in bone mass of >10% at 6 weeks postpartum. By 6 months postpartum, there was a significant mean decrease in bone density (P = 0.02) and two of the 14 patients evaluated (14%) experienced an overall bone loss of >10%.
The prolonged used of enoxaparin sodium may not cause significant bone loss during pregnancy.
评估孕期接受依诺肝素钠治疗的女性的骨密度变化。
对16名孕期接受依诺肝素钠（每日40毫克）治疗的女性的股骨近端骨密度进行连续测量。在开始治疗的2周内进行基线测量，然后在产后6 - 8周和产后6个月进行测量。
患者接受依诺肝素钠治疗的平均时长为25周（范围为19 - 32周）。从基线测量到产后6周治疗结束时，平均骨密度测量无显著变化，且在产后6周时没有患者的骨量减少超过10%。到产后6个月时，骨密度平均显著下降（P = 0.02），在接受评估的14名患者中有2名（14%）出现了超过10%的总体骨质流失。
孕期长期使用依诺肝素钠可能不会导致显著的骨质流失。
